SCHEMBL30891790

SCHEMBL30891790

COc1cc2c(-c3ccc(NC(=O)Cc4ccc(C(F)(F)F)cc4)cc3)ncnc2cc1OCC1CCNCC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDR P35968 7/20 0.46
▸ FLT4 P35916 6/20 0.46
▸ EGFR P00533 4/20 0.46
▸ FGFR1 P11362 4/20 0.46
▸ FLT1 P17948 4/20 0.46
▸ KIT P10721 4/20 0.46
▸ AXL P30530 1/20 0.45
▸ TYRO3 Q06418 1/20 0.45
▸ MERTK Q12866 1/20 0.45
▸ RAF1 P04049 2/20 0.45
▸ PDGFRB P09619 3/20 0.44
▸ AURKA O14965 1/20 0.44
▸ AURKB Q96GD4 1/20 0.44
▸ BRAF P15056 2/20 0.43
▸ HDAC1 Q13547 1/20 0.43
▸ CSF1R P07333 1/20 0.43
▸ RET P07949 1/20 0.43
▸ PDGFRA P16234 1/20 0.43
▸ DDR1 Q08345 1/20 0.43
▸ FLT3 P36888 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26536043 1.00 KDR (0.46) KDRFLT4EGFRFGFR1FLT1
SCHEMBL26102350 1.00 KDR (0.46) KDRFLT4EGFRFGFR1FLT1
Trifluoroacetic Acid SCHEMBL26103038 0.97 KIT (0.45) KDRFLT4EGFRFGFR1FLT1
Trifluoroacetic Acid SCHEMBL30394834 0.97 KIT (0.45) KDRFLT4EGFRFGFR1FLT1
SCHEMBL30891793 0.96 KIT (0.47) KDRFLT4EGFRFGFR1FLT1
SCHEMBL30891758 0.96 KIT (0.47) KDRFLT4EGFRFGFR1FLT1
SCHEMBL26099909 0.96 KIT (0.47) KDRFLT4EGFRFGFR1FLT1
SCHEMBL26099914 0.96 KIT (0.47) KDRFLT4EGFRFGFR1FLT1
SCHEMBL26101744 0.96 KIT (0.47) KDRFLT4EGFRFGFR1FLT1
SCHEMBL29238237 0.92 AURKA (0.48) KDRFLT4EGFRFGFR1FLT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118201909-A Quinazoline derivative compound and use thereof 株式会社沃若诺伊 2024-06-14 — — CN claimed
US-20260138959-A1 QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF VORONOI INC (KR) 2026-05-21 — — US disclosed
EP-4424675-A1 QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF Voronoi Inc. (KR) 2024-09-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260138959-A1 QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF PDGFRA, KIT, PDGFRB KDR 5/4885FLT4 19/4885EGFR 79/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback